Callan JMB Announces Pricing of $5.12 Million Initial Public Offering
Rhea-AI Summary
Callan JMB (NASDAQ: CJMB) has announced the pricing of its initial public offering of 1,280,000 shares at $4.00 per share, aiming to raise approximately $5.12 million in gross proceeds before deducting underwriting costs and offering expenses.
The company has granted underwriters a 45-day option to purchase up to an additional 192,000 shares at the public offering price. Trading is expected to begin on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol 'CJMB', with the offering closing around February 6, 2025.
The net proceeds will be used for sales support, marketing, customer expansion, and general corporate purposes, including working capital. Alexander Capital is serving as the managing underwriter, with Paulson Investment Company as joint book-runner.
Positive
- IPO provides $5.12M in new capital for business expansion
- Nasdaq Capital Market listing enhances company visibility and trading access
- Additional 192,000 shares option could provide extra capital if exercised
Negative
- Small IPO size might limit institutional investor interest
- Offering will cause immediate shareholder dilution
- Additional share option could cause further dilution if exercised
Insights
The pricing of Callan JMB's IPO reveals several noteworthy aspects for investors. The
The planned use of proceeds focuses on sales support, marketing and customer expansion - a clear signal that Callan is prioritizing growth over infrastructure investment. This approach could accelerate market penetration in the expanding healthcare logistics sector, particularly valuable given the increasing complexity of medical supply chains and cold storage requirements.
The inclusion of a 45-day over-allotment option for 192,000 additional shares (
The timing of this IPO amid growing healthcare logistics demands positions Callan to potentially capitalize on industry tailwinds, particularly in cold chain logistics - a critical component for handling temperature-sensitive medical products. However, investors should note that micro-cap healthcare service providers often face significant challenges in scaling operations and competing with larger, established players.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SPRING BRANCH, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the pricing of its initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offering price of
The Shares are expected to begin trading on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol “CJMB”. The Offering is expected to close on or about February 6, 2025, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds of the Offering primarily for sales support, marketing, customer expansion and general corporate purposes, including working capital.
Alexander Capital L.P. (“Alexander”) is the managing underwriter for the Offering, and Alexander and Paulson Investment Company, LLC are acting as joint book-runners for the Offering. Sichenzia Ross Ference Carmel LLP is serving as counsel to the Company, and Sullivan & Worcester LLP is serving as counsel to Alexander in connection with the Offering.
A registration statement on Form S-1, as amended (File No. 333-282879), relating to the Shares described above was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on February 4, 2025. The Offering is being made only by means of a prospectus. A copy of the final prospectus relating to the Offering may be obtained, when available, from Alexander Capital, L.P., via email: info@alexandercapitallp.com, or by calling +1 (212) 687-5650, or by standard mail at Alexander Capital L.P., 10 Drs James Parker Blvd, Suite 202 Red Bank, New Jersey 07701, Attention: Equity Capital Markets. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Callan JMB
Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward Looking Statements:
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
